Corline Biomedical Overview

  • Founded
  • 1991

Founded
  • Status
  • Public

  • Employees
  • 10

Employees
  • Stock Symbol
  • CLBIO

Stock Symbol
  • Share Price
  • $0.80

  • (As of Monday Closing)

Corline Biomedical General Information

Description

Corline Biomedical AB is involved in developing, manufacturing and marketing heparin-based solutions to improve kidney transplantation, cell therapies, and applications in the field of regenerative medicine.

Contact Information

Website
www.corline.se
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
STO
Primary Office
  • Lefflersgatan 5
  • 754 50 Uppsala
  • Sweden
+46 018-71 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Corline Biomedical Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.80 $0.83 $0.72 - $1.90 $17.7M 21.5M 10.7K -$0.02

Corline Biomedical Financials Summary

In Thousands,
USD
TTM 30-Jun-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 16,871 29,796 29,515 23,919
Revenue 1,358 822 401 112
EBITDA (358) (801) (789) (1,008)
Net Income (364) (806) (790) (1,009)
Total Assets 9,682 11,233 7,126 6,819
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Corline Biomedical Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Corline Biomedical‘s full profile, request access.

Request a free trial

Corline Biomedical Patents

Corline Biomedical Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-2793909-A4 An aqueous solution comprising a macromolecular conjugate of heparin for the treatment of blood vessels Active 22-Dec-2011 0000000000
EP-3821897-A1 Means and method of treating blood vessels Active 22-Dec-2011 0000000000
EP-3821897-B1 Means and method of treating blood vessels Active 22-Dec-2011 0000000000
EP-2793909-A1 An aqueous solution comprising a macromolecular conjugate of heparin for the treatment of blood vessels Active 22-Dec-2011 0000000000
EP-2793909-B1 An aqueous solution comprising a macromolecular conjugate of heparin for the treatment of blood vessels Active 22-Dec-2011 A61K31/727
To view Corline Biomedical’s complete patent history, request access »

Corline Biomedical Executive Team (2)

Name Title Board Seat Contact Info
Henrik Nittmar Chief Executive Officer
Gunnar Tufveson Chief Medical Officer
To view Corline Biomedical’s complete executive team members history, request access »

Corline Biomedical Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Corline Biomedical Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Corline Biomedical‘s full profile, request access.

Request a free trial